• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Lipid management: considerations in acute coronary syndrome.

作者信息

Polsani Venkateshwar R, Virani Salim S, Nambi Vijay

机构信息

Department of Medicine, Baylor College of Medicine, 6565 Fannin, Houston, TX 77030, USA.

出版信息

Curr Atheroscler Rep. 2009 Mar;11(2):149-56. doi: 10.1007/s11883-009-0024-8.

DOI:10.1007/s11883-009-0024-8
PMID:19228490
Abstract

Managing dyslipidemia is an important part of the primary and secondary prevention of coronary heart disease. Low-density lipoprotein cholesterol reduction remains the primary lipid goal. Patients who have experienced an acute coronary syndrome (ACS) are at very high risk of recurrent adverse cardiovascular events. A growing body of literature supports the concept that early and intensive treatment with statins after an ACS event decreases recurrent adverse cardiovascular events. We review available evidence pertaining to lipid alterations in ACS.

摘要

相似文献

1
Lipid management: considerations in acute coronary syndrome.
Curr Atheroscler Rep. 2009 Mar;11(2):149-56. doi: 10.1007/s11883-009-0024-8.
2
Lipid management: considerations in acute coronary syndrome.
Curr Cardiol Rep. 2008 Jul;10(4):334-41. doi: 10.1007/s11886-008-0053-x.
3
Current status of lipid management in acute coronary syndrome.急性冠状动脉综合征脂质管理的现状
J Cardiol. 2017 Aug;70(2):101-106. doi: 10.1016/j.jjcc.2017.02.004. Epub 2017 Mar 18.
4
Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.降脂治疗与急性冠状动脉综合征后 LDL-C 目标达标:一项丹麦基于人群的队列研究。
BMC Cardiovasc Disord. 2020 Jul 13;20(1):336. doi: 10.1186/s12872-020-01616-9.
5
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.使用新的美国心脏病学会/美国心脏协会胆固醇管理指南进行风险分类及其与急性冠状动脉综合征后依洛尤单抗治疗的关系。
Circulation. 2019 Nov 5;140(19):1578-1589. doi: 10.1161/CIRCULATIONAHA.119.042551. Epub 2019 Sep 2.
6
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.美国临床内分泌医师协会和美国内分泌学会血脂异常管理与心血管疾病预防指南
Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL.
7
Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.法国冠心病患者低密度脂蛋白胆固醇目标未达最佳水平。来自DYSIS II ACS/CHD研究的当代数据。
Arch Cardiovasc Dis. 2017 Mar;110(3):167-178. doi: 10.1016/j.acvd.2016.11.004. Epub 2017 Feb 13.
8
Low-Density Lipoprotein Cholesterol Target Attainment in Patients Surviving an Acute Coronary Syndrome in Thailand: Results From the Dyslipidaemia International Study (DYSIS) II.泰国急性冠状动脉综合征存活患者的低密度脂蛋白胆固醇目标达标情况:血脂异常国际研究(DYSIS II)的结果。
Heart Lung Circ. 2020 Mar;29(3):405-413. doi: 10.1016/j.hlc.2019.02.193. Epub 2019 Mar 28.
9
Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.脂蛋白(a)与急性冠状动脉综合征后复发性缺血事件风险的关系:dal-Outcomes 随机临床试验分析。
JAMA Cardiol. 2018 Feb 1;3(2):164-168. doi: 10.1001/jamacardio.2017.3833.
10
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.降低“极高”ASCVD 风险患者的靶向致动脉粥样硬化脂蛋白胆固醇目标。
Curr Diab Rep. 2019 Nov 21;19(12):146. doi: 10.1007/s11892-019-1246-y.

本文引用的文献

1
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.急性冠状动脉综合征后甘油三酯水平超出低密度脂蛋白胆固醇的影响:来自PROVE IT-TIMI 22试验的研究
J Am Coll Cardiol. 2008 Feb 19;51(7):724-30. doi: 10.1016/j.jacc.2007.10.038.
2
Effect of statin therapy before Q-wave myocardial infarction on myocardial perfusion.
Am J Cardiol. 2008 Jan 15;101(2):139-43. doi: 10.1016/j.amjcard.2007.07.059. Epub 2007 Dec 4.
3
Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein>or=100 mg/dl versus<100 mg/dl.急性冠状动脉综合征且血清低密度脂蛋白≥100mg/dl与<100mg/dl的患者出院时他汀类药物治疗的使用情况及六个月预后的比较
Am J Cardiol. 2007 Sep 15;100(6):913-8. doi: 10.1016/j.amjcard.2007.04.023. Epub 2007 Jun 26.
4
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.在高甘油三酯血症患者中,每日添加4克处方ω-3脂肪酸至每日40毫克辛伐他汀的疗效和耐受性:一项为期8周的随机、双盲、安慰剂对照研究。
Clin Ther. 2007 Jul;29(7):1354-67. doi: 10.1016/j.clinthera.2007.07.018.
5
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.二十碳五烯酸对高胆固醇血症患者主要冠脉事件的影响(日本 EPA 脂质干预研究):一项随机开放标签、终点设盲的分析。
Lancet. 2007 Mar 31;369(9567):1090-8. doi: 10.1016/S0140-6736(07)60527-3.
6
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.阿托伐他汀预处理可改善接受早期经皮冠状动脉介入治疗的急性冠状动脉综合征患者的预后:ARMYDA-ACS随机试验结果
J Am Coll Cardiol. 2007 Mar 27;49(12):1272-8. doi: 10.1016/j.jacc.2007.02.025.
7
Statins and the endothelium.他汀类药物与内皮细胞
Vascul Pharmacol. 2007 Jan;46(1):1-9. doi: 10.1016/j.vph.2006.06.012. Epub 2006 Jun 21.
8
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.脂蛋白相关磷脂酶A2及其在PROVE IT-TIMI 22(普伐他汀或阿托伐他汀评估与感染治疗-心肌梗死溶栓)试验中与急性冠状动脉综合征患者心血管结局的关联。
Circulation. 2006 Apr 11;113(14):1745-52. doi: 10.1161/CIRCULATIONAHA.105.612630. Epub 2006 Mar 14.
9
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.高密度脂蛋白而非低密度脂蛋白胆固醇水平影响急性冠脉综合征后的短期预后:MIRACL试验结果
Eur Heart J. 2005 May;26(9):890-6. doi: 10.1093/eurheartj/ehi186. Epub 2005 Mar 11.
10
A comparative crossover study of the effects of fluvastatin and pravastatin (FP-COS) on circulating autoantibodies to oxidized LDL in patients with hypercholesterolemia.氟伐他汀与普伐他汀对高胆固醇血症患者循环氧化型低密度脂蛋白自身抗体影响的比较性交叉研究(FP-COS)
J Atheroscler Thromb. 2005;12(1):41-7. doi: 10.5551/jat.12.41.